The transition of Mesenchymal Stromal Cell (MSC) therapies from clinical trials to widespread commercial use is critically dependent on scalable and robust cryopreservation processes.
This article addresses the critical challenge of standardizing mesenchymal stromal cell (MSC) cryopreservation protocols across laboratories, a key hurdle in ensuring reproducible research and successful clinical translation.
The therapeutic success of Mesenchymal Stem Cell (MSC) transplantation is critically dependent on the viability and functionality of cells post-thaw.
For researchers and drug development professionals, the effective removal of cryoprotectants like Dimethyl Sulfoxide (DMSO) post-thaw is a critical step in mesenchymal stromal cell (MSC) therapy manufacturing.
This article provides a systematic review of evidence-based strategies to enhance the post-thaw viability, recovery, and functionality of cryopreserved Mesenchymal Stromal Cells (MSCs) for clinical applications.
This comprehensive review addresses the critical challenge of dimethyl sulfoxide (DMSO) toxicity in mesenchymal stromal cell (MSC) cryopreservation, a key bottleneck in clinical cell therapy applications.
The transition of mesenchymal stromal cell (MSC) therapies from research to clinical application requires large-scale, reproducible manufacturing.
This article provides a comprehensive guide for researchers and drug development professionals on optimizing cooling rates in the cryopreservation of Mesenchymal Stem/Stromal Cells (MSCs).
The development of mesenchymal stem cells (MSCs) overexpressing therapeutic transgenes represents a frontier in regenerative medicine and oncology.
This article provides a comprehensive analysis of cryopreserving mesenchymal stromal/stem cells (MSCs) expanded in human platelet lysate (PL), a defined xeno-free alternative to fetal bovine serum (FBS).